Dr. Vulfovich on Molecular Testing in Colorectal Cancer

Video

Michel Vulfovich, MD, discusses molecular testing in colorectal cancer.

Michel Vulfovich, MD, medical director, Sickle Cell Disease and Gynecology Oncology programs, Memorial Healthcare System, discusses molecular testing in colorectal cancer (CRC).

Standard frontline practice for CRC is to put the majority of patients on chemotherapy with either FOLFOX or CAPOX plus or minus bevacizumab (Avastin), explains Vulfovich. If a patient has a KRAS wild-type mutation, they will receive cetuximab (Erbitux) or panitumumab (Vectibix).

Molecular testing is more commonly looked into for second-, third-, and fourth-line treatment, says Vulfovich. Mutations such as BRAF and HER2 have implications for prognosis. For some patients, this information is beneficial in the frontline setting; however, sometimes, even if a patient has a KRAS wild-type mutation, the mutation should not be addressed in treatment, concludes Vulfovich.

Related Videos
In this second episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, explain the challenges faced with preventing or detecting these cancers early and the understanding that is needed to develop effective early detection methods and move the needle forward.
In this first episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential for early detection multiomic assays and the work that still needs to be done to encourage their widespread use.
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD